homefeedbacksupportlog on 1-Dec-2008 
  Search
 
   
 
  Top 10s
 Hematology
  Current Top 10 by F1000 Factor
  All Time Top 10 by F1000 Factor
  Most viewed Top 10
(from all journals)
  Most viewed Top 10
(from specialty journals)
  Hidden Jewels

  Sections Covered
Anemias & Hypocellular Marrow Disorders
Bleeding & Coagulation Disorders
Hematologic Transplantation & Transfusion
Hematopoietic Stem Cells
Leukemia & Proliferative Disorders of Hematic Cells
Lymphomas & Myelomas
Non-hematopoietic Stem Cells
Pediatric Hematology
Related Sections
Perioperative Hemostasis & Transfusion Medicine


 MOST VIEWED TOP 10 (from all journals) | Hematology | calculated on 1 December 2008

The "Most Viewed Top 10 (from all journals)" Top 10 lists are generated every day. The articles are ordered by the number of times an article's evaluation(s) has/have been viewed over the past 30 days.

 browse faculty | show Most Viewed (all journals) Papers in

to email [Help]


1
Exceptional
F1000 Factor 9.0

New Finding
 Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.
Wang Z, Smith KS, …, Somervaille TC, Cleary ML
Nature 2008 Sep 17 [abstract on PubMed] [related articles] [full text]
Selected by | Jorg Baesecke
Evaluated 30 Oct 2008
 
2
Exceptional
F1000 Factor 9.0

Confirmation
New Finding
Tech Advance
 A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages.
Xia W, Hilgenbrink AR, …, Cheng JX, Low PS
Blood 2008 Oct 24 [abstract on PubMed] [related articles] [full text]
Selected by | Asok Antony
Evaluated 13 Nov 2008
 
3
Must Read
F1000 Factor 4.8

New Finding
Tech Advance
 Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH, Lossos IS, …, Zeldis JB, Habermann TM
J Clin Oncol 2008 Oct 20 26(30):4952-7 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Asher Chanan-Khan with Sikander Ailawadhi / Allessandro Gianni with Michele Magni
First evaluation 7 Nov 2008 | Latest evaluation 19 Nov 2008
 
4
Must Read
F1000 Factor 6.0

Hypothesis
 Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.
Taussig DC, Miraki-Moud F, …, Gribben JG, Bonnet D
Blood 2008 Aug 1 112(3):568-75 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Zhu Chen
Evaluated 25 Sep 2008
 
5
Must Read
F1000 Factor 6.4

New Finding
 Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D, Ganmore I, …, Green AR, Izraeli S
Lancet 2008 Oct 25 372(9648):1484-92 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jason Gotlib with Stephen Oh / Neyssa Marina with Maureen M O'Brien
First evaluation 16 Oct 2008 | Latest evaluation 7 Nov 2008
 
6
Must Read
F1000 Factor 6.6
Articles that inform your practice or change your way of thinking Changes
Clinical Practice

New Finding
 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF, Schlag R, …, Richardson PG, VISTA Trial Investigators
N Engl J Med 2008 Aug 28 359(9):906-17 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Shaji Kumar / Massimo Federico with Stefano Luminari / Klaus Podar with Sonia Vallet
First evaluation 16 Sep 2008 | Latest evaluation 24 Oct 2008
 
7
Must Read
F1000 Factor 4.8

Confirmation
New Finding
 Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS, Williams ME, …, Lemieux B, Cheson BD
J Clin Oncol 2008 Sep 20 26(27):4473-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Kensei Tobinai / Allessandro Gianni with Michele Magni
First evaluation 24 Sep 2008 | Latest evaluation 21 Oct 2008
 
8
Recommended
F1000 Factor 3.0

Confirmation
New Finding
 Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
Goodman KA, Riedel E, …, Moskowitz CH, Yahalom J
J Clin Oncol 2008 Nov 10 26(32):5240-7 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Andreas Engert with Nicole Skoetz
Evaluated 12 Nov 2008
 
9
Exceptional
F1000 Factor 8.0

Hypothesis
New Finding
 PML targeting eradicates quiescent leukaemia-initiating cells.
Ito K, Bernardi R, …, Teruya-Feldstein J, Pandolfi PP
Nature 2008 Jun 19 453(7198):1072-8 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Margaret Goodell / Suzanne Watt
First evaluation 3 Jun 2008 | Latest evaluation 9 Sep 2008
 
10
Recommended
F1000 Factor 3.0

Confirmation
 Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
Rawstron AC, Bennett FL, …, Jack AS, Hillmen P
N Engl J Med 2008 Aug 7 359(6):575-83 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Greg Bociek
Evaluated 14 Aug 2008

© 2008 Medicine Reports Ltd unless otherwise stated. < info@f1000.com >   Terms and conditions   Legal info